{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:04:32Z","timestamp":1777637072262,"version":"3.51.4"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune effector cell therapies, including chimeric antigen receptor T-cell (CAR-T) therapy and T-cell\u2013engaging antibodies, are associated with immune effector cell\u2013associated neurotoxicity syndrome (ICANS), a clinically recognized immune-mediated neurotoxicity. Among its neurological manifestations, writing impairment (dysgraphia), including paligraphia and other forms of writing disturbance, has emerged as a potentially sensitive clinical marker of higher-order cortical dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review synthesizes current clinical evidence on ICANS-associated dysgraphia, characterizes its clinical and neurocognitive features, and examines limitations in existing assessment frameworks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A structured literature search was conducted using PubMed to identify reports describing writing impairment associated with immune effector cell therapies. Studies were selected through title and abstract screening, with additional relevant reports identified through manual reference screening to address limitations of keyword-based indexing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The available evidence consists primarily of case reports and small series describing early-onset dysgraphia, frequently characterized by paligraphia, spatial disorganization, and executive dysfunction. Writing impairment typically emerges within days of infusion and often occurs during the early phase of ICANS. Although its precise frequency remains unknown, published reports suggest that dysgraphia may be under-recognized rather than truly rare. Importantly, these findings indicate that ICANS-associated dysgraphia represents a heterogeneous spectrum of writing abnormalities that is not adequately captured by current assessment tools such as the ICE score, which rely on binary evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dysgraphia represents an under-recognized but clinically meaningful manifestation of ICANS and may serve as an early and sensitive indicator of higher-order cortical dysfunction. The development of structured and quantitative handwriting assessment strategies may improve early detection and monitoring of neurotoxicity in patients receiving immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1731798","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:01:23Z","timestamp":1777442483000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy-associated dysgraphia as an early neurocognitive manifestation of immune effector cell\u2013associated neurotoxicity syndrome: clinical characteristics, mechanistic insights, and assessment challenges"],"prefix":"10.3389","volume":"17","author":[{"given":"Yasuto","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Kanazawa Medical University Hospital","place":["Kahoku, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Togen","family":"Masauji","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Kanazawa Medical University Hospital","place":["Kahoku, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Shimasaki","sequence":"additional","affiliation":[{"name":"Medical Research Institute, Kanazawa Medical University","place":["Kahoku, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58060733","article-title":"A case report on dysgraphia in a patient receiving blinatumomab: Complex characters are easy to find in a handwriting test","volume":"58","author":"Yamamoto","year":"2022","journal-title":"Med (Kaunas)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10766-5","article-title":"Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity","volume":"269","author":"Pensato","year":"2022","journal-title":"J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1125121","article-title":"Case report: Reversible punctate inflammatory foci in the corpus callosum: A novel radiological finding of CAR T-cell therapy-related neurotoxicity","volume":"14","author":"Pensato","year":"2023","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.843","article-title":"Writing the story of immune effector cell-associated neurotoxicity syndrome","volume":"5","author":"Bonny","year":"2024","journal-title":"EJHaem"},{"key":"B5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/oti.1385","article-title":"Evaluating fine motor coordination in children who are not ready for handwriting: Which test should we take","volume":"22","author":"de Vries","year":"2015","journal-title":"Occup Ther Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/0022219416633866","article-title":"Handwriting development in Spanish children with and without learning disabilities: A graphonomic approach","volume":"50","author":"Barrientos","year":"2017","journal-title":"J Learn Disabil"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cortex.2008.04.006","article-title":"Phonological dyslexia and dysgraphia: Cognitive mechanisms and neural substrates","volume":"45","author":"Rapcsak","year":"2009","journal-title":"Cortex"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-06841-6","article-title":"Pre-existing frontal lobe dysfunction signs as predictors of subsequent neurotoxicity in CAR T cell therapy: Insights from a case series","volume":"44","author":"Fontanelli","year":"2023","journal-title":"Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/nejmoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: Can we optimize early diagnosis","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6\u201312 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: A prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","volume":"87","author":"Greenbaum","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-26857-6_11","article-title":"Profile of blinatumomab and its potential in the treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"8","author":"Ribera","year":"2015","journal-title":"Onco Targets Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14121220","article-title":"CAR-T cells for the treatment of central nervous system tumours: Known and emerging neurotoxicities","volume":"14","author":"Palazzo","year":"2024","journal-title":"Brain Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw4325","article-title":"Memory engrams: Recalling the past and imagining the future","volume":"367","author":"Josselyn","year":"2020","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009174","article-title":"Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: A systematic review of clinical outcomes and management strategies","volume":"12","author":"Fleischer","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578717","article-title":"Neurotoxicity associated with chimeric antigen receptor T-cell therapy","volume":"407","author":"Wronski","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s365657","article-title":"Leukoencephalopathy during daratumumab-based therapy: A case series of two patients with multiple myeloma","volume":"15","author":"Kareem","year":"2022","journal-title":"Onco Targets Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221116329","article-title":"Capecitabine-related neurotoxicity presenting with agraphia","volume":"29","author":"Iscan","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21023","article-title":"No adverse effect of vincristine on handwriting in children after completion of therapy","volume":"49","author":"Hartman","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050591","article-title":"Change in neurocognitive function in patients who receive CAR-T cell therapies: A steep hill to climb","volume":"17","author":"Strongyli","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"key":"B40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/ccm.0b013e3182a66b76","article-title":"Cornell assessment of pediatric delirium: A valid, rapid, observational tool for screening delirium in the PICU*","volume":"42","author":"Traube","year":"2014","journal-title":"Crit Care Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.0808","article-title":"Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia","volume":"32","author":"Bhojwani","year":"2014","journal-title":"J Clin Oncol"},{"key":"B44","article-title":"Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome","volume":"19","author":"Ito","year":"1998","journal-title":"AJNR Am J Neuroradiol"},{"key":"B45","article-title":"High-dose cytarabine neurotoxicity: MR findings during the acute phase","volume":"14","author":"Vaughn","year":"1993","journal-title":"AJNR Am J Neuroradiol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1001\/archneurol.2007.62","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000443970","article-title":"Posterior reversible encephalopathy syndrome associated with sorafenib and successful retreatment","volume":"100","author":"Laruelle","year":"2018","journal-title":"Urol Int"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2008.03.007","article-title":"Posterior reversible encephalopathy syndrome during sunitinib therapy","volume":"164","author":"Cumurciuc","year":"2008","journal-title":"Rev Neurol (Paris)"},{"key":"B49","first-page":"47","article-title":"Posterior reversible encephalopathy syndrome secondary to oxaliplatin-based chemotherapy and regorafenib in metastastic colorectal cancer: Case reports and literature review","volume":"83","author":"Van Pelt","year":"2020","journal-title":"Acta Gastroenterol Belg"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0521-5","article-title":"Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: Case report and review of the literature","volume":"36","author":"Deguchi","year":"2018","journal-title":"Invest New Drugs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0306-x","article-title":"Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma","volume":"6","author":"Nakamura","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4066\/amj.2011.627","article-title":"Rituximab as a possible cause of posterior reversible encephalopathy syndrome","volume":"4","author":"Siddiqi","year":"2011","journal-title":"Australas Med J"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fneng.2013.00007","article-title":"The blood-brain barrier: an engineering perspective","volume":"6","author":"Wong","year":"2013","journal-title":"Front Neuroeng"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010022","article-title":"How to make anticancer drugs cross the blood-brain barrier to treat brain metastases","volume":"21","author":"Angeli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.15171\/bi.2016.30","article-title":"Blood-brain barrier transport machineries and targeted therapy of brain diseases","volume":"6","author":"Barar","year":"2016","journal-title":"Bioimpacts"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2368","article-title":"Modelling of the blood-brain barrier in drug discovery and development","volume":"6","author":"Cecchelli","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801076-1.00010-1","article-title":"Development of novel therapeutics targeting the blood-brain barrier: from barrier to carrier","volume":"8","author":"Li","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B59","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.tins.2020.12.002","article-title":"Blood-brain barrier dynamics to maintain brain homeostasis","volume":"44","author":"Segarra","year":"2021","journal-title":"Trends Neurosci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802155115","article-title":"Contributions of the glycocalyx, endothelium, and extravascular compartment to the blood-brain barrier","volume":"115","author":"Kutuzov","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"B62","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1053\/sonc.2002.35524","article-title":"Oxaliplatin-related side effects: characteristics and management","volume":"29","author":"Cassidy","year":"2002","journal-title":"Semin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510x(70)90013-4","article-title":"The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies","volume":"10","author":"Bradley","year":"1970","journal-title":"J Neurol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"Kane","year":"2003","journal-title":"Oncologist"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00481","article-title":"A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fukuda","year":"2017","journal-title":"Front Neurosci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.607780","article-title":"Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy","volume":"11","author":"Yamamoto","year":"2020","journal-title":"Front Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.01.003","article-title":"A review on oxaliplatin-induced peripheral nerve damage","volume":"34","author":"Argyriou","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann Neurol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/016146811001100202","article-title":"Handwriting","volume":"11","author":"Thorndike","year":"1910","journal-title":"Teachers Coll Rec"},{"key":"B70","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1023\/a:1021371425220","article-title":"Product and process evaluation of handwriting difficulties","volume":"15","author":"Rosenblum","year":"2003","journal-title":"Educ Psychol Rev"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/children10121925","article-title":"Tools and methods for diagnosing developmental dysgraphia in the digital age: a state of the art","volume":"10","author":"Danna","year":"2023","journal-title":"Children (Basel)"},{"key":"B72","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-45461-5_1","article-title":"A short review on graphonometric evaluation tools in children","volume-title":"Graphonomics in Human Body Movement. Bridging Research and Practice from Motor Control to Handwriting Analysis and Recognition. IGS 2023. Lecture Notes in Computer Science","author":"Aleman","year":"2023"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13004","article-title":"Short-term sensorimotor-based intervention for handwriting performance in elementary school children","volume":"58","author":"Alhusaini","year":"2016","journal-title":"Pediatr Int"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3390\/children10020223","article-title":"Validation of the concise assessment scale for children\u2019s handwriting (BHK) in an italian population","volume":"10","author":"Loizzo","year":"2023","journal-title":"Children (Basel)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196098","article-title":"Inter-relationships between objective handwriting features and executive control among children with developmental dysgraphia","volume":"13","author":"Rosenblum","year":"2018","journal-title":"PloS One"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.5014\/ajot.56.4.446","article-title":"A validity study of the Evaluation Tool of Children\u2019s Handwriting-Cursive","volume":"56","author":"Koziatek","year":"2002","journal-title":"Am J Occup Ther"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/pep.0000000000000050","article-title":"Reliability of the detailed assessment of speed of handwriting on Flemish children","volume":"26","author":"Simons","year":"2014","journal-title":"Pediatr Phys Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/0022219416633127","article-title":"Early grade writing assessment: an instrument model","volume":"50","author":"Jim\u00e9nez","year":"2017","journal-title":"J Learn Disabil"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ridd.2010.09.015","article-title":"Handwriting characteristics among secondary students with and without physical disabilities: a study with a computerized tool","volume":"32","author":"Li-Tsang","year":"2011","journal-title":"Res Dev Disabil"},{"key":"B80","volume-title":"Concise evaluation scale for children\u2019s handwriting","author":"Hamstra-Bletz","year":"1987"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237575","article-title":"Acquisition of handwriting in children with and without dysgraphia: a computational approach","volume":"15","author":"Gargot","year":"2020","journal-title":"PloS One"},{"key":"B82","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41746-018-0049-x","article-title":"Automated human-level diagnosis of dysgraphia using a consumer tablet","volume":"1","author":"Asselborn","year":"2018","journal-title":"NPJ Digit Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41598-020-60011-8","article-title":"Extending the spectrum of dysgraphia: a data driven strategy to estimate handwriting quality","volume":"10","author":"Asselborn","year":"2020","journal-title":"Sci Rep"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.humov.2008.02.011","article-title":"Handwriting process and product characteristics of children diagnosed with developmental coordination disorder","volume":"27","author":"Rosenblum","year":"2008","journal-title":"Hum Mov Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/13638490600667964","article-title":"Using data visualization and signal processing to characterize the handwriting process","volume":"9","author":"Rosenblum","year":"2006","journal-title":"Pediatr Rehabil"},{"key":"B86","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1038\/s41598-017-05105-6","article-title":"Children\u2019s first handwriting productions show a rhythmic structure","volume":"7","author":"Pagliarini","year":"2017","journal-title":"Sci Rep"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.1216","article-title":"Analysis of handwriting of children during treatment for acute lymphoblastic leukemia","volume":"37","author":"Reinders-Messelink","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.eswa.2023.120740","article-title":"CNN feature and classifier fusion on novel transformed image dataset for dysgraphia diagnosis in children","volume":"231","author":"Kunhoth","year":"2023","journal-title":"Expert Syst Appl"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2022.110647","article-title":"Dysgraphia disorder forecasting and classification technique using intelligent deep learning approaches","volume":"120","author":"Devi","year":"2023","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1007\/978-981-99-1909-3_28","article-title":"Dysgraphia detection using machine learning-based techniques: A survey","volume-title":"Emerging Trends in Expert Applications and Security. ICE-TEAS 2023. Lecture Notes in Networks and Systems","author":"Agarwal","year":"2023"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42979-025-03927-0","article-title":"AI-enhanced child handwriting analysis: a framework for the early screening of dyslexia and dysgraphia","volume":"6","author":"Rangasrinivasan","year":"2025","journal-title":"SN Comput Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731798\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:01:26Z","timestamp":1777442486000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1731798\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":91,"alternative-id":["10.3389\/fimmu.2026.1731798"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1731798","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"article-number":"1731798"}}